place

Saint Alban's Abbey, Mainz

10th-century churches in Germany14th-century Roman Catholic church buildings in GermanyBurial sites of the Ottonian dynastyChristian monasteries established in the 8th centuryChristianity in Rhineland-Palatinate
History of MainzMonasteries in Rhineland-PalatinateRoman Catholic churches in MainzRomanesque architecture in Germany
Mainz1631
Mainz1631

St. Alban's Abbey, Mainz (Stift St. Alban vor Mainz) originated as a Benedictine abbey, founded in 787 or 796 by Archbishop Richulf (787–813) in honour of Saint Alban of Mainz, located to the south of Mainz on the hill later called the Albansberg. It was turned into a collegiate foundation (Herrenstift) in 1442. The buildings were entirely destroyed in 1552, although the foundation retained a legal existence until its formal dissolution in 1802. The abbey was initially renowned for its school, and for its beautiful church. The school was the origin of the Carolingian court school. One of its famous teachers was Rabanus Maurus, born c 780 in Mainz. The importance of the place was reflected in the extraordinary size of the hall. The church was inaugurated on 1 December 805 by Richulf and remained the largest church of Mainz until construction of Mainz Cathedral was begun by Willigis.

Excerpt from the Wikipedia article Saint Alban's Abbey, Mainz (License: CC BY-SA 3.0, Authors, Images).

Saint Alban's Abbey, Mainz
Am Rosengarten, Mainz Oberstadt (Oberstadt)

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: Saint Alban's Abbey, MainzContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 49.99 ° E 8.28 °
placeShow on map

Address

Am Rosengarten 29
55131 Mainz, Oberstadt (Oberstadt)
Rhineland-Palatinate, Germany
mapOpen on Google Maps

Mainz1631
Mainz1631
Share experience

Nearby Places

BioNTech
BioNTech

BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Some days later the vaccine also received an emergency approval in the United States, Canada and Switzerland. On 21 December 2020, the European Commission approved BioNTech/Pfizer's coronavirus vaccine in accordance with the positive recommendation of the European Medicines Agency (EMA).